Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib
- PMID:16554105
- DOI:10.1016/j.lungcan.2006.01.008
Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib
Abstract
Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), produces radiographic regression and symptom relief in patients with refractory advanced non-small cell lung cancer. However, it remains controversial whether gefitinib improves patient survival. We report three cases of refractory metastatic non-small cell lung cancer who have survived approximately 3 years since they first started gefitinib. These long-term survivors were Japanese female non-smokers with adenocarcinoma, who often had multiple lung metastases and were effectively re-treated with gefitinib. One patient had a surgical specimen available for DNA extraction and showed deletions in exon 19 of EGFR. Our experience suggests that gefitinib may improve long-term survival in selected patients. Further studies are required to identify biomarkers downstream of the EGFR mutations that are involved in multiple lung metastases and which could identify those patients who may benefit from gefitinib re-treatment.
Comment in
-
Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.Lung Cancer. 2006 Jul;53(1):123-4. doi: 10.1016/j.lungcan.2006.04.004. Epub 2006 May 24. Lung Cancer. 2006. PMID:16723171 No abstract available.
Similar articles
-
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.Lung Cancer. 2006 Jan;51(1):89-96. doi: 10.1016/j.lungcan.2005.09.002. Epub 2005 Nov 14. Lung Cancer. 2006. PMID:16290256
-
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. J Clin Oncol. 2008. PMID:18458038 Clinical Trial.
-
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.Am J Respir Crit Care Med. 2008 Oct 15;178(8):847-53. doi: 10.1164/rccm.200803-389OC. Epub 2008 Jun 26. Am J Respir Crit Care Med. 2008. PMID:18583573
-
Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.Curr Med Res Opin. 2012 Oct;28(10):1699-708. doi: 10.1185/03007995.2012.728525. Epub 2012 Oct 2. Curr Med Res Opin. 2012. PMID:22978775 Review.
-
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.肺癌。2011年3月,71(3):249 - 57。doi: 10.1016 / j.lungcan.2010.12.008. Epub 2011 Jan 8. Lung Cancer. 2011. PMID:21216486 Review.
Cited by4articles
-
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study.Ther Adv Med Oncol. 2021 May 22;13:17588359211018022. doi: 10.1177/17588359211018022. eCollection 2021. Ther Adv Med Oncol. 2021. PMID:34093743 Free PMC article.
-
Long-lasting response to afatinib that persisted after treatment discontinuation in a case ofEGFR-mutated lung adenocarcinoma.BMJ Case Rep. 2019 Jan 31;12(1):e227383. doi: 10.1136/bcr-2018-227383. BMJ Case Rep. 2019. PMID:30709831 Free PMC article.
-
High efficacy of gefitinib in the treatment of EGFR mutation-positive advanced non-small cell lung adenocarcinoma: A case report.Oncol Lett. 2014 Sep;8(3):1320-1322. doi: 10.3892/ol.2014.2269. Epub 2014 Jun 19. Oncol Lett. 2014. PMID:25120716 Free PMC article.
-
Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report.Case Rep Oncol. 2013 Mar 29;6(1):189-96. doi: 10.1159/000350680. Print 2013 Jan. Case Rep Oncol. 2013. PMID:23626560 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous